NICE recommends against use of Faslodex (fulvestrant) to delay growth of estrogen-receptor-positive breast cancer.-AstraZeneca
The National Institute of Health and Care Excellence (NICE) released draft guidance recommending against use of Faslodex (fulvestrant) from AstraZeneca as an option for delaying growth of estrogen-receptor-positive breast cancer that has spread to other parts of the body in patients who have not yet been treated with hormonal therapy. NICE considers that Faslodex does not show that it extends survival more than less expensive therapies.
Faslodex has showed it can delay cancer growth by about three months more than aromatase inhibitors but according to NICE, it is too early to determine from the available evidence whether this effect translates into an increase in overall survival benefit.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins